Sales of Roche's flu drug Tamiflu rose 32 percent to 517 million...

Sales of Roche's flu drug Tamiflu rose 32 percent to 517 million francs in the first three months of the year as the company enjoyed additional demand due to the swine flu pandemic.

Other makers of flu drugs and vaccines, such as GlaxoSmithKline Plc (GSK.L), Sanofi-Aventis SA (SASY.PA) and Novartis AG (NOVN.VX), are also expected to enjoy a first-quarter sales boost, despite recent government moves to cut some vaccine orders due to excess supplies.